Related Experiment Videos
Urocortins: putative role in cardiovascular disease
Christopher J Charles1, Miriam T Rademaker, A Mark Richards
1Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand. chris.charles@chmeds.ac.nz
Current Medicinal Chemistry. Cardiovascular and Hematological Agents
|August 24, 2004
Summary
Urocortin (Ucn) shows promise for treating heart failure by improving cardiovascular function and reducing hormonal stress. New related peptides, Ucn II and Ucn III, may offer similar benefits without activating stress pathways.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- Urocortin (Ucn) and its receptor (CRF-R2beta) are present in the heart and vasculature, suggesting a role in cardiovascular regulation.
- Increased Ucn expression is observed in failing hearts, indicating its involvement in cardiac compromise.
Purpose of the Study:
- To investigate the effects of Ucn in experimental ovine heart failure.
- To explore the potential of Ucn II and Ucn III as therapeutic agents for heart failure.
Main Methods:
- Administration of Ucn in an ovine model of heart failure.
- Assessment of cardiovascular, hormonal, and renal parameters.
- Review of existing literature on Ucn II and Ucn III selectivity for CRF receptors.
Main Results:
- Ucn demonstrated significant cardiovascular benefits, including reduced cardiac preload/afterload and increased cardiac output.
- Ucn inhibited key hormonal axes (vasopressin, endothelin, renin-angiotensin-aldosterone) and promoted natriuresis/diuresis.
- Ucn II and Ucn III show high selectivity for CRF-R2beta, unlike Ucn, potentially avoiding stress-related ACTH activation.
Conclusions:
- Ucn exhibits potent cardiovascular, hormonal, and renal effects beneficial in heart failure management.
- Ucn II and Ucn III represent a novel therapeutic avenue for heart failure, potentially offering benefits without stress axis activation.
- Further research is warranted to confirm the clinical utility of Ucn II and Ucn III in human heart failure.